logo

Eyepoint Pharmaceuticals, Inc. (EYPT)



Trade EYPT now with
  Date
  Headline
7/15/2019 7:04:49 AM EyePoint Pharmaceuticals Appoints Wendy DiCicco To Board
6/13/2019 7:08:08 AM EyePoint Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28/2019 9:29:36 AM EyePoint Pharma Announces Pricing Of Underwritten Public Offering Of 10.53 Mln Shares At $1.90/shr
3/14/2019 6:12:17 AM EyePoint Pharma Q2 Net Loss $11.6 Miln Or $0.12/shr Vs Loss Of $5.8 Mln Or $0.13/Shr Last Year
2/4/2019 7:08:43 AM EyePoint Pharmaceuticals Announces U.S. Commercial Launch Of YUTIQ 0.18 Mg In The United States
1/28/2019 7:03:59 AM EyePoint Pharmaceuticals Appoints David Guyer To Board
1/3/2019 7:10:42 AM EyePoint Now Expects DEXYCUTM Commercial Launch In Q1, Earlier Than Prior Guidance Of H1
11/27/2018 4:09:40 PM EyePoint Pharmaceuticals Appoints Ron Honig As SVP, General Counsel & Company Secretary
11/12/2018 7:06:44 AM EyePoint Pharma Announces Assignment Of Permanent J-Code For DEXYCU By Center For Medicare And Medicaid Services
11/6/2018 6:13:43 AM EyePoint Pharma Q1 Net Loss $33.1 Mln Or $0.44/Shr Vs Loss Of $6.0 Mln Or $0.15/Shr Last Year
10/29/2018 7:07:55 AM EyePoint Pharmaceuticals Presents Positive YUTIQ 24-month Follow-up Data At AAO 2018 Annual Meeting
10/18/2018 7:17:41 AM EyePoint Pharma Announces Data Highlighting YUTIQ To Be Presented At AAO 2018 Annual Meeting
10/15/2018 6:33:40 AM EyePoint Pharma Gets FDA Approval Of YUTIQ
9/12/2018 6:03:22 AM EyePoint Pharmaceuticals Q4 Net Loss Widens To $53.2 Mln Or $1.15/shr From $18.5 Mln Or $0.52/shr Last Year
9/10/2018 7:01:15 AM EyePoint Pharmaceuticals Elects Göran Ando As Its Next Chairman Of Board
8/15/2018 7:05:06 AM EyePoint Pharma Appoints John Weet As SVP, Regulatory Affairs & Quality
8/1/2018 7:09:11 AM EyePoint Pharmaceuticals Appoints David Price As CFO
  
 
>